{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T19:35:39Z","timestamp":1790796939755,"version":"4.1.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,1,16]],"date-time":"2023-01-16T00:00:00Z","timestamp":1673827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,1,16]],"date-time":"2023-01-16T00:00:00Z","timestamp":1673827200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Headache Pain"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Many migraine patients do not respond adequately to conventional preventive treatments and are therefore described as treatment\/medically resistant or difficult to treat cases. Calcitonin gene-related peptide monoclonal antibodies are a relatively novel molecular treatment for episodic and chronic migraine that have been shown to be effective in short duration clinical trials in approximately 40\u201350% of all chronic migraine patients. Patient Related Outcome Measures (PROM) or Quality of Life (QoL) questionnaires are used to help measure response to treatment in migraine. Although some open label extension studies have become available for erenumab, there is a lack of real-world data pertaining to quality of life in the medium to long-term for chronic and treatment resistant migraine patients.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A total of 177 treatment resistant CM patients were started on erenumab (70\u2009mg or 140\u2009mg subcutaneous injection every 4 weeks) in our three specialist Headache Clinics. Of these, 174 had their first injection between December 2018 and October 2019. All patients were evaluated with the following PROM: the Headache Impact Test\u2212\u20096, Migraine Associated Disability Assessment test and Migraine-Specific QoL Questionnaire, before starting treatment with erenumab and at intervals of 3\u201312\u2009months after starting treatment. The decision to continue treatment was based on subjective clinical improvement of at least 30% (as reported by the patient), supported with diaries and QoL questionnaires. We present here the QoL measurements for this group of 177 patients. Prior preventive migraine treatments included conventional oral prophylactic medications (such as topiramate, candesartan, propranolol, or amitriptyline), at least two cycles of PREEMPT protocol onabotulinumtoxin A or (in a small number of cases) neuromodulation with single pulse Transcranial Magnetic Stimulation.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Of the 177 patients who started treatment with erenumab, 68\/177 (38.4%) stopped during the first year, either due to lack of efficacy (no significant benefit or only minimal improvement) and\/or possible side effects. 109\/177 (61.6%) patients reported clinically significant improvement after 6\u201312\u2009months and wished to stay on treatment. Twelve of these 109 patients subsequently stopped treatment in the period between 1 year and up to June 2021 (mainly due to a worsening of their migraine). Therefore, a total of 97\/177 patients (54.8%) remained on treatment as of June 2021 (duration of treatment 17\u201330\u2009months, median of 25\u2009months).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Approximately 55% of treatment resistant or difficult to treat CM patients who trialled erenumab in our clinics reported a subjective benefit and were still on treatment after 17\u201330\u2009months.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s10194-022-01536-3","type":"journal-article","created":{"date-parts":[[2023,1,16]],"date-time":"2023-01-16T10:02:47Z","timestamp":1673863367000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Medium-term real-world data for erenumab in 177 treatment resistant or difficult to treat chronic migraine patients: persistence and patient reported outcome measures after 17\u201330\u2009months"],"prefix":"10.1186","volume":"24","author":[{"given":"Emma","family":"Troy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arif A.","family":"Shrukalla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alina","family":"Buture","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katie","family":"Conaty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther","family":"Macken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roisin","family":"Lonergan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane","family":"Melling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niamh","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eamonn","family":"Shaikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kieran","family":"Birrane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther M.","family":"Tomkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter J.","family":"Goadsby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin H.","family":"Ruttledge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,1,16]]},"reference":[{"issue":"9","key":"1536_CR1","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/j.clineuro.2010.05.011","volume":"112","author":"J Stone","year":"2010","unstructured":"Stone J, Carson A, Duncan R, Roberts R, Warlow C, Hibberd C et al (2010) Who is referred to neurology clinics? - the diagnoses made in 3781 new patients. Clin Neurol Neurosurg 112(9):747\u2013751. https:\/\/doi.org\/10.1016\/j.clineuro.2010.05.011","journal-title":"Clin Neurol Neurosurg"},{"issue":"1","key":"1536_CR2","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1186\/s10194-020-01208-0","volume":"21","author":"TJ Steiner","year":"2020","unstructured":"Steiner TJ, Stovner LJ, Jensen R, Uluduz D, Katsarava Z, on behalf of Lifting The Burden: the Global Campaign against H (2020) Migraine remains second among the world\u2019s causes of disability, and first among young women: findings from GBD2019. J Headache Pain 21(1):137. https:\/\/doi.org\/10.1186\/s10194-020-01208-0","journal-title":"J Headache Pain"},{"issue":"5","key":"1536_CR3","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1111\/j.1468-1331.2011.03612.x","volume":"19","author":"M Linde","year":"2012","unstructured":"Linde M, Gustavsson A, Stovner LJ, Steiner TJ, Barr\u00e9 J, Katsarava Z et al (2012) The cost of headache disorders in Europe: the Eurolight project. Eur J Neurol 19(5):703\u2013711. https:\/\/doi.org\/10.1111\/j.1468-1331.2011.03612.x","journal-title":"Eur J Neurol"},{"issue":"1","key":"1536_CR4","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1186\/s10194-018-0946-z","volume":"19","author":"P Martelletti","year":"2018","unstructured":"Martelletti P, Schwedt TJ, Lanteri-Minet M, Quintana R, Carboni V, Diener HC et al (2018) My migraine voice survey: a global study of disease burden among individuals with migraine for whom preventive treatments have failed. J Headache Pain 19(1):115. https:\/\/doi.org\/10.1186\/s10194-018-0946-z","journal-title":"J Headache Pain"},{"issue":"1","key":"1536_CR5","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s10194-019-1040-x","volume":"20","author":"L D'Antona","year":"2019","unstructured":"D'Antona L, Matharu M (2019) Identifying and managing refractory migraine: barriers and opportunities? J Headache Pain 20(1):89. https:\/\/doi.org\/10.1186\/s10194-019-1040-x","journal-title":"J Headache Pain"},{"issue":"9","key":"1536_CR6","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1177\/0333102413485658","volume":"33","author":"Headache Classification Committee of the International Headache Society","year":"2013","unstructured":"Headache Classification Committee of the International Headache Society (2013) The international classification of headache disorders, 3rd edition (beta version). Cephalalgia. 33(9):629\u2013808. https:\/\/doi.org\/10.1177\/0333102413485658","journal-title":"Cephalalgia."},{"issue":"9","key":"1536_CR7","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1016\/S1474-4422(19)30146-2","volume":"18","author":"HC Diener","year":"2019","unstructured":"Diener HC, Dodick D, Evers S, Holle D, Jensen RH, Lipton RB et al (2019) Pathophysiology, prevention, and treatment of medication overuse headache. Lancet Neurol 18(9):891\u2013902. https:\/\/doi.org\/10.1016\/S1474-4422(19)30146-2","journal-title":"Lancet Neurol"},{"issue":"10161","key":"1536_CR8","doi-asserted-by":"publisher","first-page":"2280","DOI":"10.1016\/S0140-6736(18)32534-0","volume":"392","author":"U Reuter","year":"2018","unstructured":"Reuter U, Goadsby PJ, Lanteri-Minet M, Wen S, Hours-Zesiger P, Ferrari MD et al (2018) Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study. Lancet. 392(10161):2280\u20132287. https:\/\/doi.org\/10.1016\/S0140-6736(18)32534-0","journal-title":"Lancet."},{"issue":"11","key":"1536_CR9","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1007\/s40265-018-0944-0","volume":"78","author":"MA Erenumab","year":"2018","unstructured":"Erenumab MA (2018) First global approval. Drugs. 78(11):1157\u20131161. https:\/\/doi.org\/10.1007\/s40265-018-0944-0","journal-title":"Drugs."},{"issue":"6","key":"1536_CR10","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1016\/j.celrep.2020.01.029","volume":"30","author":"F Garces","year":"2020","unstructured":"Garces F, Mohr C, Zhang L, Huang CS, Chen Q, King C et al (2020) Molecular insight into recognition of the CGRPR complex by migraine prevention therapy Aimovig (Erenumab). Cell Rep 30(6):1714\u201323.e6. https:\/\/doi.org\/10.1016\/j.celrep.2020.01.029","journal-title":"Cell Rep"},{"issue":"20","key":"1536_CR11","doi-asserted-by":"publisher","first-page":"e2309","DOI":"10.1212\/WNL.0000000000007497","volume":"92","author":"SJ Tepper","year":"2019","unstructured":"Tepper SJ, Diener HC, Ashina M, Brandes JL, Friedman DI, Reuter U et al (2019) Erenumab in chronic migraine with medication overuse: subgroup analysis of a randomized trial. Neurology. 92(20):e2309\u2013e2320. https:\/\/doi.org\/10.1212\/WNL.0000000000007497","journal-title":"Neurology."},{"issue":"8","key":"1536_CR12","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1023\/a:1026119331193","volume":"12","author":"M Kosinski","year":"2003","unstructured":"Kosinski M, Bayliss MS, Bjorner JB, Ware JE Jr, Garber WH, Batenhorst A et al (2003) A six-item short-form survey for measuring headache impact: the HIT-6. Qual Life Res 12(8):963\u2013974. https:\/\/doi.org\/10.1023\/a:1026119331193","journal-title":"Qual Life Res"},{"issue":"4","key":"1536_CR13","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1185\/0300799019117017","volume":"17","author":"AJ Dowson","year":"2001","unstructured":"Dowson AJ (2001) Assessing the impact of migraine. Curr Med Res Opin 17(4):298\u2013309. https:\/\/doi.org\/10.1185\/0300799019117017","journal-title":"Curr Med Res Opin"},{"issue":"6 Suppl 1","key":"1536_CR14","doi-asserted-by":"publisher","first-page":"S20","DOI":"10.1212\/wnl.56.suppl_1.s20","volume":"56","author":"WF Stewart","year":"2001","unstructured":"Stewart WF, Lipton RB, Dowson AJ, Sawyer J (2001) Development and testing of the migraine disability assessment (MIDAS) questionnaire to assess headache-related disability. Neurology. 56(6 Suppl 1):S20\u2013S28. https:\/\/doi.org\/10.1212\/wnl.56.suppl_1.s20","journal-title":"Neurology."},{"issue":"4","key":"1536_CR15","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1046\/j.1526-4610.1998.3804295.x","volume":"38","author":"P Jhingran","year":"1998","unstructured":"Jhingran P, Osterhaus JT, Miller DW, Lee JT, Kirchdoerfer L (1998) Development and validation of the migraine-specific quality of life questionnaire. Headache. 38(4):295\u2013302. https:\/\/doi.org\/10.1046\/j.1526-4610.1998.3804295.x","journal-title":"Headache."},{"issue":"6","key":"1536_CR16","doi-asserted-by":"publisher","first-page":"707","DOI":"10.2165\/00019053-199813060-00007","volume":"13","author":"P Jhingran","year":"1998","unstructured":"Jhingran P, Davis SM, LaVange LM, Miller DW, Helms RW (1998) MSQ: migraine-specific quality-of-life questionnaire. Further investigation of the factor structure. Pharmacoeconomics. 13(6):707\u2013717. https:\/\/doi.org\/10.2165\/00019053-199813060-00007","journal-title":"Pharmacoeconomics."},{"key":"1536_CR17","doi-asserted-by":"publisher","first-page":"687697","DOI":"10.3389\/fneur.2021.687697","volume":"12","author":"A Tziakouri","year":"2021","unstructured":"Tziakouri A, Tsangari H, Michaelides C (2021) Assessment of the effect of Erenumab on efficacy and quality-of-life parameters in a cohort of migraine patients with treatment failure in Cyprus. Front Neurol 12:687697. https:\/\/doi.org\/10.3389\/fneur.2021.687697","journal-title":"Front Neurol"},{"issue":"8","key":"1536_CR18","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1007\/s40261-021-01059-w","volume":"41","author":"M Eghtesadi","year":"2021","unstructured":"Eghtesadi M, Leroux E, Pag\u00e9 G (2021) Real-life response to Erenumab in a therapy-resistant case series of migraine patients from the province of Qu\u00e9bec, eastern Canada. Clin Drug Investig 41(8):733\u2013739. https:\/\/doi.org\/10.1007\/s40261-021-01059-w","journal-title":"Clin Drug Investig"},{"issue":"1","key":"1536_CR19","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s10194-020-01127-0","volume":"21","author":"G Lambru","year":"2020","unstructured":"Lambru G, Hill B, Murphy M, Tylova I, Andreou AP (2020) A prospective real-world analysis of erenumab in refractory chronic migraine. J Headache Pain 21(1):61. https:\/\/doi.org\/10.1186\/s10194-020-01127-0","journal-title":"J Headache Pain"},{"issue":"1","key":"1536_CR20","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1111\/head.14218","volume":"62","author":"J Gladstone","year":"2022","unstructured":"Gladstone J, Chhibber S, Minhas J, Neish CS, Power GS, Lan Z et al (2022) Real-world persistence of erenumab for preventive treatment of chronic and episodic migraine: retrospective real-world study. Headache. 62(1):78\u201388. https:\/\/doi.org\/10.1111\/head.14218","journal-title":"Headache."},{"issue":"1","key":"1536_CR21","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/s10194-022-01448-2","volume":"23","author":"P Irimia","year":"2022","unstructured":"Irimia P, Garcia-Azorin D, Nunez M, Diaz-Cerezo S, Garcia de Polavieja P, Panni T et al (2022) Persistence, use of resources and costs in patients under migraine preventive treatment: the PERSEC study. J Headache Pain 23(1):78. https:\/\/doi.org\/10.1186\/s10194-022-01448-2","journal-title":"J Headache Pain"},{"issue":"2","key":"1536_CR22","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1177\/03331024211053571","volume":"42","author":"U Reuter","year":"2022","unstructured":"Reuter U, Ehrlich M, Gendolla A, Heinze A, Klatt J, Wen S et al (2022) Erenumab versus topiramate for the prevention of migraine \u2013 a randomised, double-blind, active-controlled phase 4 trial. Cephalalgia. 42(2):108\u2013118. https:\/\/doi.org\/10.1177\/03331024211053571","journal-title":"Cephalalgia."},{"issue":"22","key":"1536_CR23","doi-asserted-by":"publisher","first-page":"e2724","DOI":"10.1212\/WNL.0000000000012029","volume":"96","author":"PJ Goadsby","year":"2021","unstructured":"Goadsby PJ, Reuter U, Lanteri-Minet M, da Silva P, Lima G, Hours-Zesiger P, Fernandes C et al (2021) Long-term efficacy and safety of Erenumab: results from 64 weeks of the LIBERTY study. Neurology. 96(22):e2724\u2013e2735. https:\/\/doi.org\/10.1212\/WNL.0000000000012029","journal-title":"Neurology."},{"issue":"5","key":"1536_CR24","doi-asserted-by":"publisher","first-page":"1716","DOI":"10.1111\/ene.14715","volume":"28","author":"M Ashina","year":"2021","unstructured":"Ashina M, Goadsby PJ, Reuter U, Silberstein S, Dodick DW, Xue F et al (2021) Long-term efficacy and safety of erenumab in migraine prevention: results from a 5-year, open-label treatment phase of a randomized clinical trial. Eur J Neurol 28(5):1716\u20131725. https:\/\/doi.org\/10.1111\/ene.14715","journal-title":"Eur J Neurol"},{"issue":"10","key":"1536_CR25","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1177\/03331024211006045","volume":"41","author":"KL Haywood","year":"2021","unstructured":"Haywood KL, Achana F, Nichols V, Pearce G, Box B, Muldoon L et al (2021) Measuring health-related quality of life in chronic headache: a comparative evaluation of the chronic headache quality of life questionnaire and headache impact test (HIT-6). Cephalalgia. 41(10):1100\u20131123. https:\/\/doi.org\/10.1177\/03331024211006045","journal-title":"Cephalalgia."},{"issue":"3","key":"1536_CR26","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1097\/WCO.0000000000000689","volume":"32","author":"M Torres-Ferrus","year":"2019","unstructured":"Torres-Ferrus M, Alpuente A, Pozo-Rosich P (2019) How much do calcitonin gene-related peptide monoclonal antibodies improve the quality of life in migraine? A patient's perspective. Curr Opin Neurol 32(3):395\u2013404. https:\/\/doi.org\/10.1097\/WCO.0000000000000689","journal-title":"Curr Opin Neurol"},{"issue":"5","key":"1536_CR27","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1007\/s11136-012-0230-7","volume":"22","author":"R Rendas-Baum","year":"2013","unstructured":"Rendas-Baum R, Bloudek LM, Maglinte GA, Varon SF (2013) The psychometric properties of the migraine-specific quality of life questionnaire version 2.1 (MSQ) in chronic migraine patients. Qual Life Res 22(5):1123\u20131133. https:\/\/doi.org\/10.1007\/s11136-012-0230-7","journal-title":"Qual Life Res"},{"issue":"7","key":"1536_CR28","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1177\/0333102417731348","volume":"38","author":"KL Haywood","year":"2018","unstructured":"Haywood KL, Mars TS, Potter R, Patel S, Matharu M, Underwood M (2018) Assessing the impact of headaches and the outcomes of treatment: a systematic review of patient-reported outcome measures (PROMs). Cephalalgia. 38(7):1374\u20131386. https:\/\/doi.org\/10.1177\/0333102417731348","journal-title":"Cephalalgia."},{"issue":"8","key":"1536_CR29","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1038\/nrneurol.2016.93","volume":"12","author":"A May","year":"2016","unstructured":"May A, Schulte LH (2016) Chronic migraine: risk factors, mechanisms and treatment. Nat Rev Neurol 12(8):455\u2013464. https:\/\/doi.org\/10.1038\/nrneurol.2016.93","journal-title":"Nat Rev Neurol"},{"issue":"5","key":"1536_CR30","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1177\/0333102410391487","volume":"31","author":"KY Park","year":"2011","unstructured":"Park KY, Fletcher JR, Raddant AC, Russo AF (2011) Epigenetic regulation of the calcitonin gene-related peptide gene in trigeminal glia. Cephalalgia. 31(5):614\u2013624. https:\/\/doi.org\/10.1177\/0333102410391487","journal-title":"Cephalalgia."},{"issue":"6","key":"1536_CR31","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1111\/head.13843","volume":"60","author":"L Pellesi","year":"2020","unstructured":"Pellesi L, Do TP, Ashina H, Ashina M, Burstein R (2020) Dual therapy with anti-CGRP monoclonal antibodies and Botulinum toxin for migraine prevention: is there a rationale? Headache. 60(6):1056\u20131065. https:\/\/doi.org\/10.1111\/head.13843","journal-title":"Headache."},{"issue":"11","key":"1536_CR32","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1016\/S1474-4422(17)30299-5","volume":"16","author":"Global Burden of Disease - Neurological Disorders Collaborator Group","year":"2017","unstructured":"Global Burden of Disease - Neurological Disorders Collaborator Group (2017) Global, regional, and national burden of neurological disorders during 1990-2015: a systematic analysis for the global burden of disease study 2015. Lancet Neurol 16(11):877\u2013897. https:\/\/doi.org\/10.1016\/S1474-4422(17)30299-5","journal-title":"Lancet Neurol"}],"container-title":["The Journal of Headache and Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-022-01536-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s10194-022-01536-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-022-01536-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,16]],"date-time":"2023-01-16T10:02:49Z","timestamp":1673863369000},"score":1,"resource":{"primary":{"URL":"https:\/\/thejournalofheadacheandpain.biomedcentral.com\/articles\/10.1186\/s10194-022-01536-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,16]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1536"],"URL":"https:\/\/doi.org\/10.1186\/s10194-022-01536-3","relation":{},"ISSN":["1129-2377"],"issn-type":[{"value":"1129-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,16]]},"assertion":[{"value":"19 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 December 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not Applicable. The datasets used and\/or analyzed in this manuscript come from the completion of an audit which was registered in the hospitals where patients were seen. Verbal informed consent was obtained from all patients.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not Applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"ET: \u201cNo Conflict\u201d.AS: \u201cNo Conflict\u201d.AB: has received a PhD Scholarship from the Headache Clinical Trial Funds at the Hull University Teaching Hospitals NHS Trust, UK, and honorarium as a speaker from Novartis and conference travel grant from Eli Lilly.KC: \u201cNo Conflict\u201d.EM: \u201cNo Conflict\u201d.RL: \u201cNo Conflict\u201d.JM: \u201cNo Conflict\u201d.NL: \u201cNo Conflict\u201d.ES: has received honoraria from Teva.KB: has received personal fees from Novartis.EMT: has received personal fees and\/or honoraria from Allegran\/Abbvie, Pfizer,\u00a0Novartis, Teva, and Lundbeck.PJG: reports,\u00a0over the last 36\u2009months, grants and personal fees from Eli-Lilly and Company, grant from Celgene, and personal fees from Aeon Biopharma, Allergan\/Abbvie, Amgen, Biodelivery Sciences International,\u00a0Biohaven Pharmaceuticals Inc., CoolTech LLC, Dr Reddys,\u00a0Epalex, GlaxoSmithKline, Impel Neuropharma, Lundbeck, Novartis, Praxis, Sanofi, Satsuma, and Teva Pharmaceuticals, and personal fees for advice through Gerson Lehrman Group, Guidepoint, SAI Med Partners, Vector Metric,\u00a0and fees for educational materials from CME Outfitters, Omnia Education, WebMD, and publishing royalties or fees from Massachusetts Medical Society, Oxford University Press, UptoDate and Wolters Kluwer, and for medicolegal advice in headache, and a patent magnetic stimulation for headache (No. WO2016090333 A1) assigned to eNeura without fee.\u00a0MR: has received personal fees and\/or honoraria from Allegran\/Abbvie, Pfizer,\u00a0Grunenthal, Eli-Lilly, Novartis, Teva, Lundbeck and MSD.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"5"}}